Entries by groupH
Moving forwards…2017
The groupH team would like to say Thank You. This short video is an art installation bringing light / season / sound and biology together and from the outside resembles a bee hive that is made up of thousands of little hexagons. If you know in which London borough this installation is currently located, e-mail […]
Does the EU price of Strimvelis create a new ‘glass ceiling’?
The recent announcement of the European authority’s pricing strategy for Strimvelis, the world’s second approved gene therapy, is in line with the predictions groupH made a year ago in “Nature Biotechnology” – but does Strimvelis prove our point or is it a one-off? In our article, “The Payers’ perspective on gene therapies”, we suggested that […]
groupH at World Orphan Drug Congress, Brussels, 15 – 17 November, 2016
Join Erik Holzinger in Brussels. We would be very happy to meet up or to share our perspectives from the conference in case you are not attending this event.
Will indication value-based pricing become a reality in Europe?
groupH’s Market Access practice, headed by Nicolas Touchot, has recently been part of a collaboration to research the feasibility and attractiveness of indication value-based pricing (IBP) in key EU countries. Many targeted medicines are developed for different diseases and indications with common underlying biological mechanisms. The product benefit and therefore the ‘value’ is almost certain […]
groupH in 2015 and beyond…
This year, we reached a big milestone – groupH turned 10 years old. In case you missed it, our visual communicators Michael and Marcelle put together a short video – the story of groupH as a retrospective. In addition to the many thousands of PowerPoint slides, countless spreadsheets and hundreds of physician, payer and patient […]
Enhancing decision makers’ understanding of rare diseases – a case study
In the process of assessing novel healthcare opportunities, groupH recognises that the clearest picture comes from understanding the viewpoint of all stakeholders involved. By triangulating input from patients, healthcare providers and payers, we can provide the most granular and robust insights to best inform decision making and understanding from all stakeholders in value dossiers and […]
